CRDMO Market - Global Outlook & Forecast 2024-2029

List of Tables

The global Contract Research, Development, and Manufacturing Organization (CRDMO) market is expected to grow at a CAGR of 9.00% from 2023 to 2029.

Recent Developments, Mergers & Acquisitions in the Global CRDMO Market

Recent Developments:

In 2023, Lonza expanded its CRDMO capabilities by opening a new development and manufacturing facility dedicated to cell and gene therapies, enhancing support for advanced therapeutic modalities.
Catalent, a prominent CRDMO, launched a comprehensive suite of services for the development and manufacturing of mRNA vaccines, aligning with the increasing demand for RNA-based therapies.

Mergers and Acquisitions:

In 2021, WuXi AppTec acquired Oxyrane UK, further strengthening cell and gene therapy service offerings for global customers.
Curia acquired LakePharma, a biologics-focused CRO and CDMO, in March 2021 to enhance its biopharmaceutical development and manufacturing capacity.
Charles River Laboratories to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell and Gene Therapy Development in 2021.

MARKET TRENDS & OPPORTUNITIES

Focus on Personalized Medicine

The shift toward personalized medicine is creating significant opportunities for the global CRDMO market, as pharmaceutical companies require specialized expertise in developing targeted therapies. This demand is particularly high in oncology and rare diseases, where personalized approaches are critical. CRDMOs are investing in capabilities to support precision medicine, including advanced analytical and manufacturing technologies that ensure scalability and regulatory compliance.

Integration of Advanced Technologies

The global CRDMO market is undergoing significant transformation with the integration of advanced technologies such as artificial intelligence, machine learning, digital twins, and automation. As the pharmaceutical and biotechnology sectors seek more efficient and cost-effective drug development and production processes, CRDMOs have positioned themselves at the forefront of technological innovation to cater to these evolving needs. These advancements are not only enhancing the precision and speed of drug development but are also establishing new standards in data-driven decision-making, supply chain resilience, and quality control. One of the most impactful technological integrations in the market has been the use of AI and ML for predictive analytics and process optimization. AI models are utilized to predict outcomes and optimize the use of resources during the development and manufacturing phases.

INDUSTRY RESTRAINTS

Need for Experienced and Skilled Workforce

A significant challenge in the CRDMO market is the demand for an experienced workforce. The CRDMO (Contract Research, Development, and Manufacturing Organization) sector requires specialized knowledge across various functions, including regulatory affairs, quality assurance, process development, and project management. As companies increasingly outsource their research and manufacturing needs, the demand for professionals with expertise in these areas has intensified. The need for skilled personnel is further compounded by the industry's shift toward more complex biologics and advanced therapies, which necessitate a deep understanding of sophisticated production techniques and regulatory requirements. Moreover, the market is also witnessing a surge in the adoption of digital technologies and automation. As companies strive to improve efficiency and reduce time-to-market, skilled workers proficient in the latest technologies, such as AI, machine learning, and data analytics, are increasingly essential.

SEGMENTATION INSIGHTS

INSIGHTS BY FUNCTION

The global CRDMO market by functions is segmented into clinical development & supplies, commercial manufacturing, discovery, and preclinical development. The clinical development & supplies segment holds the most significant market share. This segment growth is fueled by increasing demand for clinical trial support and supply chain management solutions for investigational products. Clinical development and supplies are integral to the market, shaping how drugs progress through testing to eventual commercialization. As pharmaceutical and biotech companies continue to outsource critical phases of drug development, the Clinical Development & Supplies segment is anticipated to play a pivotal role in accelerating product timelines and addressing the growing complexity of clinical trial requirements. Furthermore, in the CRDMO market, preclinical development holds the highest CAGR at 10.92% during the forecast period. The rising need for in vivo and in vitro toxicology studies, safety pharmacology, and formulation development is driving this segment's growth. As regulatory scrutiny intensifies and the demand for comprehensive preclinical data increases, companies are relying more heavily on CRDMOs to navigate preclinical requirements efficiently and cost-effectively.

Segmentation by Functions

Clinical Development & Supplies
Commercial Manufacturing
Discovery
Preclinical Development

INSIGHTS BY MODALITY

The global CRDMO market by modality is segmented into small molecule and biologics. In terms of modality, small-molecule drugs constitute the largest market share, reflecting the continued prevalence of small molecules in drug development. Despite the rise of biologics, small molecules remain fundamental due to their wide range of applications and established manufacturing processes. CRDMOs specializing in small molecules are leveraging advancements in formulation and production to support ongoing innovation. Furthermore, technological advancements in both small molecule and biologics production are transforming the CRDMO landscape. Innovations such as continuous manufacturing, digital process monitoring, and AI-driven optimization are helping to enhance efficiency, ensure quality, and reduce time to market. These advancements also align with regulatory expectations for higher standards of compliance and sustainability.

Segmentation by Modality

Small Molecule
Biologics

GEOGRAPHICAL ANALYSIS

North America leads the global CRDMO market, with the highest revenue share due to strong R&D investments and the presence of major pharmaceutical companies. The region's regulatory environment and focus on personalized medicine further drive demand for CRDMO services. The U.S. and Canada are the primary markets driving this region's demand for outsourced drug development and manufacturing services, catering to both emerging biotechs and established pharmaceutical giants. In the U.S., a significant portion of demand for CRDMO services comes from biopharma companies looking to streamline operations and reduce costs in the drug development pipeline.

Europe follows as a key market, supported by a robust pharmaceutical industry and growing investment in biologics and cell therapies. The APAC region is witnessing rapid growth, driven by increasing clinical trials and rising pharmaceutical outsourcing activities in countries like China and India. This rapid growth is being fueled by a combination of factors, including the region's large and growing pharmaceutical industry, competitive manufacturing costs, and increasing investments in research and development (R&D). Furthermore, the Middle East and Latin America are also emerging as new markets for CRDMO services, particularly as governments in these regions promote pharmaceutical research and manufacturing.

Segmentation by Geography

APAC
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Singapore
Europe
- Germany
- The U.K.
- France
- Italy
- Spain
- Switzerland
- Belgium
North America
- The U.S.
- Canada
Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
Latin America
- Brazil
- Mexico
- Argentina

COMPETITIVE LANDSCAPE

The CRDMO market is highly competitive, with leading players like Lonza Group, WuXi, Catalent, Inc., Sai Life Sciences Limited, Syngene International Limited, Jubilant Biosys Ltd., and Thermo Fisher Scientific Inc. These companies are continually expanding their service offerings, investing in state-of-the-art facilities, and acquiring smaller companies to strengthen their market presence. Digital transformation and the adoption of data analytics and AI are shaping the CRDMO market, enabling firms to enhance operational efficiency and meet regulatory standards. As competition intensifies, companies are focusing on building end-to-end capabilities to differentiate their services and capture a larger share of the growing demand for comprehensive drug development solutions.

Key Company Profiles

Aragen Life Sciences Ltd.
Catalent, Inc
Jubilant Biosys Ltd.
Lonza
Sai Life Sciences Limited
Syngene International Limited
Thermo Fisher Scientific Inc.
WuXi AppTec

Other Prominent Vendors

BioDuro-Sundia
WuXi Biologics
PHT Industries
Esco Aster Pte. Ltd
Charles River Laboratories
Siegfried Holding AG
Recipharm AB
Cambrex Corporation
Piramal Pharma Limited
Rentschler Biopharma SE
Asymchem Inc.
AGC Biologics
Curia Global, Inc.
Quotient Sciences
Aurigene Pharmaceutical Services Ltd.
MabPlex International Co., Ltd.
CordenPharma
Bluepharma
Angelini S.p.a.
Adragos Pharma
LAXAI
FUJIFILM Diosynth Biotechnologies
Pharmaron
Anthem Biosciences

KEY QUESTIONS ANSWERED:

1. What is the growth rate of the global CRDMO market?

2. How big is the global CRDMO market?

3. What are the significant trends in the CRDMO market?

4. Which region dominates the global CRDMO market share?

5. Who are the key players in the global CRDMO market?

Product Code: ARZ241206

1. SCOPE & COVERAGE

1.1. MARKET DEFINITION
- 1.1.1. INCLUSIONS
- 1.1.2. EXCLUSIONS
- 1.1.3. MARKET ESTIMATION CAVEATS
1.2. SEGMENTS COVERED & DEFINITION
- 1.1.1 MARKET SEGMENTATION BY FUNCTION
- 1.2.1. MARKET SEGMENTATION BY MODALITY
- 1.1.2 REGIONS & COUNTRIES COVERED
1.3. MARKET DERIVATION
- 1.3.1. HISTORIC, BASE, & FORECAST YEARS

2. PREMIUM INSIGHTS

2.1. OPPORTUNITY POCKETS
- 2.1.1. MARKET MATURITY INDICATOR
- 2.1.2. REGIONAL INSIGHTS
2.2. REPORT OVERVIEW
2.3. RECENT DEVELOPMENTS, MERGERS & ACQUISITIONS DATA
2.4. OPPORTUNITIES & CHALLENGE ANALYSIS
2.5. SEGMENT ANALYSIS
2.6. REGIONAL ANALYSIS
2.7. COMPETITIVE LANDSCAPE
2.8. KEY QUESTIONS ANSWERED

3. MARKET AT A GLANCE

4. INTRODUCTION

4.1. OVERVIEW
4.2. INCREASE IN CONSOLIDATION AND TRANSACTIONS TO BUILD CRDMOS
4.3. STRATEGIC MOVES OF COMPANIES IN CRDMO MARKET
4.4. INITIAL STAGE OF CRDMO VALUE CHAIN
4.5. MANUFACTURING
4.6. DISTRIBUTION & SERVICE PROVIDERS

5. MARKET OPPORTUNITIES & TRENDS

5.1. INCREASED DEMAND FOR OUTSOURCING
5.2. FOCUS ON PERSONALIZED MEDICINE
5.3. INCREASE IN TRANSACTION TO BUILD CRDMOS

6. MARKET GROWTH ENABLERS

6.1. RISE IN DEMAND IN BIOPHARMACEUTICALS
6.2. INTEGRATION OF ADVANCED TECHNOLOGIES
6.3. RISE IN DEMAND FOR CLINICAL TRIALS

7. MARKET RESTRAINTS

7.1. NEED FOR EXPERIENCED AND SKILLED WORKFORCE
7.2. EXCESS PRODUCTION CAPACITY AND ASSOCIATED COSTS
7.3. REGULATORY COMPLIANCE RISKS

8. MARKET LANDSCAPE

8.1. MARKET OVERVIEW
8.2. MARKET SIZE & FORECAST
8.3. FIVE FORCES ANALYSIS
- 8.3.1. THREAT OF NEW ENTRANTS
- 8.3.2. BARGAINING POWER OF SUPPLIERS
- 8.3.3. BARGAINING POWER OF BUYERS
- 8.3.4. THREAT OF SUBSTITUTES
- 8.3.5. COMPETITIVE RIVALRY

9. FUNCTION

9.1. MARKET SNAPSHOT & GROWTH ENGINE
9.2. MARKET OVERVIEW
9.3. CLINICAL DEVELOPMENT AND SUPPLIES
- 9.3.1. MARKET OVERVIEW
- 9.3.2. MARKET SIZE & FORECAST
- 9.3.3. MARKET BY GEOGRAPHY
9.4. COMMERCIAL MANUFACTURING
- 9.4.1. MARKET OVERVIEW
- 9.4.2. MARKET SIZE & FORECAST
- 9.4.3. MARKET BY GEOGRAPHY
9.5. DISCOVERY
- 9.5.1. MARKET OVERVIEW
- 9.5.2. MARKET SIZE & FORECAST
- 9.5.3. MARKET BY GEOGRAPHY
9.6. PRECLINICAL DEVELOPMENT
- 9.6.1. MARKET OVERVIEW
- 9.6.2. MARKET SIZE & FORECAST
- 9.6.3. MARKET BY GEOGRAPHY

10. MODALITY

10.1. MARKET SNAPSHOT & GROWTH ENGINE
10.2. MARKET OVERVIEW
10.3. SMALL MOLECULE
- 10.3.1. MARKET OVERVIEW
- 10.3.2. MARKET SIZE & FORECAST
- 10.3.3. MARKET BY GEOGRAPHY
10.4. BIOLOGICS
- 10.4.1. MARKET OVERVIEW
- 10.4.2. MARKET SIZE & FORECAST
- 10.4.3. MARKET BY GEOGRAPHY

11. GEOGRAPHY

11.1. MARKET SNAPSHOT & GROWTH ENGINE
11.2. GEOGRAPHIC OVERVIEW

12. APAC

12.1. MARKET OVERVIEW
12.2. MARKET SIZE & FORECAST
12.3. FUNCTION
- 12.3.1. MARKET SIZE & FORECAST
12.4. MODALITY
- 12.4.1. MARKET SIZE & FORECAST
12.5. KEY COUNTRIES
12.6. CHINA: MARKET SIZE & FORECAST
12.7. INDIA: MARKET SIZE & FORECAST
12.8. JAPAN: MARKET SIZE & FORECAST
12.9. SOUTH KOREA: MARKET SIZE & FORECAST
12.10. AUSTRALIA: MARKET SIZE & FORECAST
12.11. INDONESIA: MARKET SIZE & FORECAST
12.12. SINGAPORE: MARKET SIZE & FORECAST

13. EUROPE

13.1. MARKET OVERVIEW
13.2. MARKET SIZE & FORECAST
13.3. FUNCTION
- 13.3.1. MARKET SIZE & FORECAST
13.4. MODALITY
- 13.4.1. MARKET SIZE & FORECAST
13.5. KEY COUNTRIES
13.6. GERMANY: MARKET SIZE & FORECAST
13.7. UK: MARKET SIZE & FORECAST
13.8. FRANCE: MARKET SIZE & FORECAST
13.9. ITALY: MARKET SIZE & FORECAST
13.10. SPAIN: MARKET SIZE & FORECAST
13.11. SWITZERLAND: MARKET SIZE & FORECAST
13.12. BELGIUM: MARKET SIZE & FORECAST

14. NORTH AMERICA

14.1. MARKET OVERVIEW
14.2. MARKET SIZE & FORECAST
14.3. FUNCTION
- 14.3.1. MARKET SIZE & FORECAST
14.4. MODALITY
- 14.4.1. MARKET SIZE & FORECAST
14.5. KEY COUNTRIES
14.6. US: MARKET SIZE & FORECAST
14.7. CANADA: MARKET SIZE & FORECAST

15. MIDDLE EAST & ASIA

15.1. MARKET OVERVIEW
15.2. MARKET SIZE & FORECAST
15.3. FUNCTION
- 15.3.1. MARKET SIZE & FORECAST
15.4. MODALITY
- 15.4.1. MARKET SIZE & FORECAST
15.5. KEY COUNTRIES
15.6. UAE: MARKET SIZE & FORECAST
15.7. SAUDI ARABIA: MARKET SIZE & FORECAST
15.8. SOUTH AFRICA: MARKET SIZE & FORECAST

16. LATIN AMERICA

16.1. MARKET OVERVIEW
16.2. MARKET SIZE & FORECAST
16.3. FUNCTION
- 16.3.1. MARKET SIZE & FORECAST
16.4. MODALITY
- 16.4.1. MARKET SIZE & FORECAST
16.5. KEY COUNTRIES
16.6. BRAZIL: MARKET SIZE & FORECAST
16.7. MEXICO: MARKET SIZE & FORECAST
16.8. ARGENTINA: MARKET SIZE & FORECAST

17. COMPETITIVE LANDSCAPE

17.1. COMPETITION OVERVIEW
17.2. MARKET SHARE ANALYSIS

18. KEY COMPANY PROFILES

18.1. ARAGEN LIFE SCIENCES LTD.
- 18.1.1. BUSINESS OVERVIEW
- 18.1.2. SERVICE OFFERINGS
- 18.1.3. KEY STRATEGIES
- 18.1.4. KEY STRENGTHS
- 18.1.5. KEY OPPORTUNITIES
18.2. CATALENT, INC
- 18.2.1. BUSINESS OVERVIEW
- 18.2.2. SERVICE OFFERINGS
- 18.2.3. KEY STRATEGIES
- 18.2.4. KEY STRENGTHS
- 18.2.5. KEY OPPORTUNITIES
18.3. JUBILANT BIOSYS LTD.
- 18.3.1. BUSINESS OVERVIEW
- 18.3.2. SERVICE OFFERINGS
- 18.3.3. KEY STRATEGIES
- 18.3.4. KEY STRENGTHS
- 18.3.5. KEY OPPORTUNITIES
18.4. LONZA
- 18.4.1. BUSINESS OVERVIEW
- 18.4.2. SERVICE OFFERINGS
- 18.4.3. KEY STRATEGIES
- 18.4.4. KEY STRENGTHS
- 18.4.5. KEY OPPORTUNITIES
18.5. SAI LIFE SCIENCES LIMITED
- 18.5.1. BUSINESS OVERVIEW
- 18.5.2. SERVICE OFFERINGS
- 18.5.3. KEY STRATEGIES
- 18.5.4. KEY STRENGTHS
- 18.5.5. KEY OPPORTUNITIES
18.6. SYNGENE INTERNATIONAL LIMITED
- 18.6.1. BUSINESS OVERVIEW
- 18.6.2. SERVICE OFFERINGS
- 18.6.3. KEY STRATEGIES
- 18.6.4. KEY STRENGTHS
- 18.6.5. KEY OPPORTUNITIES
18.7. THERMO FISHER SCIENTIFIC INC.
- 18.7.1. BUSINESS OVERVIEW
- 18.7.2. SERVICE OFFERINGS
- 18.7.3. KEY STRATEGIES
- 18.7.4. KEY STRENGTHS
- 18.7.5. KEY OPPORTUNITIES
18.8. WUXI APPTEC
- 18.8.1. BUSINESS OVERVIEW
- 18.8.2. SERVICE OFFERINGS
- 18.8.3. KEY STRATEGIES
- 18.8.4. KEY STRENGTHS
- 18.8.5. KEY OPPORTUNITIES

19. OTHER PROMINENT VENDORS

19.1. BIODURO-SUNDIA
- 19.1.1. BUSINESS OVERVIEW
- 19.1.2. SERVICE OFFERINGS
19.2. WUXI BIOLOGICS
- 19.2.1. BUSINESS OVERVIEW
- 19.2.2. SERVICE OFFERINGS
19.3. PHT INDUSTRIES
- 19.3.1. BUSINESS OVERVIEW
- 19.3.2. SERVICE OFFERINGS
19.4. ESCO ASTER PTE. LTD
- 19.4.1. BUSINESS OVERVIEW
- 19.4.2. SERVICE OFFERINGS
19.5. CHARLES RIVER LABORATORIES
- 19.5.1. BUSINESS OVERVIEW
- 19.5.2. SERVICE OFFERINGS
19.6. SIEGFRIED HOLDING AG
- 19.6.1. BUSINESS OVERVIEW
- 19.6.2. SERVICE OFFERINGS
19.7. RECIPHARM AB.
- 19.7.1. BUSINESS OVERVIEW
- 19.7.2. SERVICE OFFERINGS
19.8. CAMBREX CORPORATION
- 19.8.1. BUSINESS OVERVIEW
- 19.8.2. SERVICE OFFERINGS
19.9. PIRAMAL PHARMA LIMITED
- 19.9.1. BUSINESS OVERVIEW
- 19.9.2. SERVICE OFFERINGS
19.10. RENTSCHLER BIOPHARMA SE
- 19.10.1. BUSINESS OVERVIEW
- 19.10.2. SERVICE OFFERINGS
19.11. ASYMCHEM INC.
- 19.11.1. BUSINESS OVERVIEW
- 19.11.2. SERVICE OFFERINGS
19.12. AGC BIOLOGICS
- 19.12.1. BUSINESS OVERVIEW
- 19.12.2. SERVICE OFFERINGS
19.13. CURIA GLOBAL, INC.
- 19.13.1. BUSINESS OVERVIEW
- 19.13.2. SERVICE OFFERINGS
19.14. QUOTIENT SCIENCES
- 19.14.1. BUSINESS OVERVIEW
- 19.14.2. SERVICE OFFERINGS
19.15. AURIGENE PHARMACEUTICAL SERVICES LTD.
- 19.15.1. BUSINESS OVERVIEW
- 19.15.2. SERVICE OFFERINGS
19.16. MABPLEX INTERNATIONAL CO. LTD.
- 19.16.1. BUSINESS OVERVIEW
- 19.16.2. SERVICE OFFERINGS
19.17. CORDENPHARMA
- 19.17.1. BUSINESS OVERVIEW
- 19.17.2. SERVICE OFFERINGS
19.18. BLUEPHARMA
- 19.18.1. BUSINESS OVERVIEW
- 19.18.2. SERVICE OFFERINGS
19.19. ANGELINI S.P.A
- 19.19.1. BUSINESS OVERVIEW
- 19.19.2. SERVICE OFFERINGS
19.20. ADRAGOS PHARMA
- 19.20.1. BUSINESS OVERVIEW
- 19.20.2. SERVICE OFFERINGS
19.21. LAXAI
- 19.21.1. BUSINESS OVERVIEW
- 19.21.2. SERVICE OFFERINGS
19.22. FUJIFILM DIOSYNTH BIOTECHNOLOGIES
- 19.22.1. BUSINESS OVERVIEW
- 19.22.2. SERVICE OFFERINGS
19.23. PHARMARON
- 19.23.1. BUSINESS OVERVIEW
- 19.23.2. SERVICE OFFERINGS
19.24. ANTHEM BIOSCIENCES
- 19.24.1. BUSINESS OVERVIEW
- 19.24.2. SERVICE OFFERINGS

20. REPORT SUMMARY

20.1. KEY TAKEAWAYS
20.2. STRATEGIC RECOMMENDATIONS

21. QUANTITATIVE SUMMARY

21.1. MARKET BY GEOGRAPHY
21.2. APAC
- 21.2.1. FUNCTION: MARKET SIZE & FORECAST
- 21.2.2. MODALITY: MARKET SIZE & FORECAST
21.3. EUROPE
- 21.3.1. FUNCTION: MARKET SIZE & FORECAST
- 21.3.2. MODALITY: MARKET SIZE & FORECAST
21.4. NORTH AMERICA
- 21.4.1. FUNCTION: MARKET SIZE & FORECAST
- 21.4.2. MODALITY: MARKET SIZE & FORECAST
21.5. MIDDLE EAST & AFRICA
- 21.5.1. FUNCTION: MARKET SIZE & FORECAST
- 21.5.2. MODALITY: MARKET SIZE & FORECAST
21.6. LATIN AMERICA
- 21.6.1. FUNCTION: MARKET SIZE & FORECAST
- 21.6.2. MODALITY: MARKET SIZE & FORECAST

22. APPENDIX

22.1. RESEARCH METHODOLOGY
22.2. RESEARCH PROCESS
22.3. REPORT ASSUMPTIONS & CAVEATS
- 22.3.1. KEY CAVEATS
- 22.3.2. CURRENCY CONVERSION
22.4. ABBREVIATIONS